Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)

Nuclear Medicine and Biology

Volumn 37, Issue 1, 2010, Pages 85-93

  Papi, Stefano ^a   Martano, Luigi ^a   Garaboldi, Lucia ^a   Rossi, Annalisa ^a   Cremonesi, Marta ^a   Grana, Chiara Maria ^a   Paolucci, Daniele ^a   Sansovini, Maddalena ^b   Paganelli, Giovanni ^a   Chinol, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

90Y; High dose Zevalin; Radiation protection; Radiolabeling; Radiopharmacy; RIT

Indexed keywords

IBRITUMOMAB TIUXETAN;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG MEGADOSE; DRUG PURITY; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; ISOTOPE LABELING; OCCUPATIONAL SAFETY; PROCESS OPTIMIZATION; QUALITY CONTROL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION PROTECTION; RADIATION SAFETY; RADIOACTIVITY; STAFF; THERMOLUMINESCENCE DOSIMETER;

ANTIBODIES, MONOCLONAL; FINGERS; HUMANS; ISOTOPE LABELING; OCCUPATIONAL EXPOSURE; QUALITY CONTROL; RADIATION DOSAGE; RADIOPHARMACEUTICALS; SAFETY;

EID: 72649101694     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.08.012     Document Type: Article

References (44)

1. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
2. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 2453-2463
3. Witzig T.E., Flinn I.W., Gordon L.I., Emmanouilides C., Czuczman M.S., Saleh M.N., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 3262-3269
4. + B-cell non-Hodgkin's lymphoma. J Clin Oncol 7 (1999) 3793-3803
5. Wiseman G.A., Gordon L.I., Multani P.S., Witzig T.E., Spies S., Bartlett N.L., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood 99 (2002) 4336-4342
6. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. Semin Oncol 30 Suppl 17 (2003) 11-16
7. 90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 20 (2005) 185-188
8. Emmanouilides C., Witzig T.E., Gordon L.I., Vo K., Wiseman G.A., Flinn I.W., et al. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 47 (2006) 629-636
9. Goldenberg D.M., and Sharkey R.M. Advances in cancer therapy with radiolabeled monoclonal antibodies. Q J Nucl Med Mol Imaging 50 (2006) 248-264
10. Goldenberg D.M., Sharkey R.M., Paganelli G., Barbet J., and Chatal J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24 (2006) 823-834
11. 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46 (2005) 620-633
12. 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. British Journal of Haematology 139 (2007) 590-599
13. 90Y-conjugates: risks and safety. Eur J Nucl Med Mol Imaging 33 (2006) 1321-1327
14. Patent # RM 2002 A000071.
15. Ehrlich P. On immunity. With special reference to the relationship between distribution and action of antigens. J Royal Inst Publ Health 15 (1907) 321-340
16. Pressman D., and Keighley G. The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic antikidney serum. J Immunol 59 (1948) 141-146
17. Pressman D., Day E.D., and Blau M. The use of paired labelling in the determination of tumor localizing antibodies. Cancer Res 17 (1957) 845
18. Bale W.F., Spar I.L., and Goodland R.L. Experimental radiation therapy of tumor with I-131-carrying antibodies to fibrin. Cancer Res 20 (1960) 1488
19. 90Y generator. Radiochim Acta 93 (2005) 111-113
20. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27 (2000) 766-777
21. Wiseman G.A., White C.A., Sparks R.B., Erwin W.D., Podoloff D.A., Lamonica D., et al. Biodistribution and dosimetry results from a Phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39 (2001) 181-194
22. Wiseman G.A., Leigh B., Erwin W.D., Lamonica D., Kornmehl E., Spies S.M., et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94 Suppl 4 (2002) 1349-1357
23. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 44 (2003) 465-474
24. Wiseman G.A., Leigh B.R., Erwin W.D., Sparks R.B., Podoloff D.A., Schilder R.J., et al. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 18 (2003) 165-178
25. Wiseman G.A., Leigh B.R., Dunn W.L., Stabin M.G., and White C.A. Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. Cancer Biother Radiopharm 18 (2003) 253-258
26. Witzig T.E., White C.A., Gordon L.I., Wiseman G.A., Emmanouilides C., Murray J.L., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21 (2003) 1263-1270
27. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger C.C., Nelp W.B., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329 (1993) 1219-1224
28. 90Y-hLL2) anti-CD22 monoclonal antibody (MAb). J Nucl Med 41 Suppl (2000) 31
29. Gopal A.K., Gooley T.A., Golden J.B., Maloney D.G., Bensinger W.I., Petersdorf S.H., et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Trasplantation 27 (2001) 593-599
30. Gopal A.K., Rajendran J.G., Gooley T.A., Pagel J.M., Fisher D.R., Petersdorf S., et al. A Phase II study of myeloablative I-131-anti CD-20 (Tositumomab) radioimmunotherapy and autologous hematopoietic stem cell transplantation (ASCT) for adults ≥60 years of age with high-risk relapsed or refractory B-cell lymphoma. Blood (ASH Annual Meeting Abstracts) 106 (2005) 487
31. 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic progenitor cell transplant in relapsed or refractory B-cell NHL. Blood 98 (2001) 677a-678a
32. 90YZ) doses higher than 4 mCi/kg may be safely combined with high-dose beam and autotransplant: the role for dosimetry. Blood 104 (2004) 1162
33. Devizzi L., Seregni E., Guidetti A., Forni C., Coliva A., Magni M., et al. High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting. Blood (ASH Annual Meeting Abstracts) 106 (2005) 2737
34. Krishnan A., Raubitschek A., Forman S.J., Fung H., Molina A., Yamauchi D., et al. New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 106 (2005) 681
35. Nademanee A., Forman S., Molina A., Fung H., Smith D., Dagis A., et al. A Phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
36. Shimoni A., Zwas T., Oksman Y., Hardan I., Shem-Tov N., Yerushalmi R., et al. Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma. Blood (ASH Annual Meeting Abstracts) 106 (2005) 1131
37. 90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplantation 40 (2007) 1007-1017
38. 90yttrium ibritumomab tiuxetan) treatment with PBSC support in refractory-resistant NHL patients: preliminary results of a Phase I/II study. Blood 106 (2005) Abstract 488
39. 90yttrium ibritumomab tiuxetan (Zevalin) with PBSC support in refractory-resistant NHL patients: a Phase I/II study. Blood 108 (2006) Abstract 2720
40. 90yttrium ibritumomab tiuxetan with PBSC support in refractory-resistant NHL patients: preliminary results of a Phase I/II study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) Abstract 7587
41. Devizzi L., Seregni E., Guidetti A., Forni C., Coliva A., Magni M., et al. High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has promising activity, minimal toxicity and full feasibility in an outpatient setting. Blood 108 (2006) Abstract 3047
42. 90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 24 18S (2006) Abstract 7535
43. 90Y) ibritumomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 104 (2004) Abstract 897
44. 90Y-Zevalin therapy. Results of a prospective multicentre trial. Nuklearmedizin 45 (2006) 82-86